A comparison of the treatment of acute myocardial infarction between St. Petersburg, Russia and Seattle, Washington

International Journal of Cardiology

Volumn 53, Issue 1, 1996, Pages 29-36

  Reiss, James Arthur ^a   Every, Nathan ^b   Weaver, W Douglas ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Myocardial infarction; Percutaneous coronary angioplasty; Russia; Thrombolysis; Treatment comparison

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES; USSR;

EID: 0030053761     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(95)02498-0     Document Type: Article

References (19)

1. Nanda A, Nossikov A, Remigijus P et al. Health in the central and eastern countries of the WHO European Region: an overview. World Health Statistics Quarterly 1993; 46(3): 158-165.
2. Weaver WD, Eisenberg MS, Martin JS et al. Myocardial Infarction Triage and Intervention Project - Phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990; 15: 925-31.
3. Central Intelligence Agency Staff. The World Factbook, 1991-1992. McLean, VA: Brasseys (US), 1992.
4. Death rates by selected cause, age and sex for persons 60 and over: 1960-1990. Demographic Yearbook - Special Issue. New York: United Nations, 1993.
5. Fibrinolytic Therapy Trialists' Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.
6. Weaver W D, Cerqueira M, Hallstrom AP et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Project. J Am Med Assoc 1993; 270: 1211-1216.
7. Eisenberg MS, Aghababian RV, Bossaert L et al. Thrombolytic therapy. Ann Emergency Med 1992; 2 (part 2): 417-427.
8. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-549.
9. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477-1482.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
11. Gruppo Italiano per lo Studio della streptochinasi Nell-Infarto Miocardica (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
12. LATE Study Group. Late Assessment of Thrombolytic Therapy Efficacy study with alteplase 6-24 h after onset of AMI. Lancet 1993; 342: 767-772.
13. EMERAS Collaborative Group. Randomized trial of late thrombolysis in patients with suspected AMI. Lancet 1993; 342: 767-772.
14. ISIS-1 (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. ISIS-1. Lancet 1986; 2: 57-66.
15. Bleich SD, Nichols TC, Schumacher RR et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 56: 1412-1417.
16. Hsia J, Hamilton WP, Kleiman N et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437.
17. Pepine CJ. The importance of timing of thrombolytic therapy as shown in clinical trials. Clin Cardiol 1990; 13 (suppl VIII): 12-17.
18. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. N Engl J Med 1989; 320: 618-627.
19. Alpert JS, Rippe JM. Ischemic Heart Disease. Manual of Cardiovascular Diagnosis and Therapy, 3rd Edn. Boston, MA: Little, Brown and Company, 1988.